Pardes Biosciences Inc (PRDS) Peer Comparison

$2.16

$0.00 (0.00%)

As on 08-Sep-2023 09:30EDT

Market cap

$134 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	134	17,326	13,400	12,305	12,277
Revenue ($ Mln)	--	2,782	2,436	670	1,664
Net Profit ($ Mln)	-96.28	491.50	860.62	-319.95	413.60
Net Margin (%)	--	17.67	35.33	-47.79	24.86
RoE (%)	-57.38	110.09	42.98	-71.14	430.03
Price to Earnings	--	36.49	17.01	--	31.17
Price-To-Book	0.37	39.43	7.27	26.44	83.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	0.00	1,027.56	57.91	10.42	139.30
Gross Profit	--	432.44	1,553.15	243.23	520.81
Operating Expenses	82.88	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-84.61	278.70	201.48	-178.51	267.53
Other Income	0.00	7.07	-0.20	0.77	-1.67
Profit before Tax	-76.14	282.86	234.35	-172.71	248.92
Provision for Tax	20.14	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-96.28	245.37	182.28	-176.49	202.13
Minority Interest	0.00	--	--	19.82	--
Consolidated Profit	-65.36	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	155.39	386.39	2,488.43	398.52	169.80
Minority Interest	0.00	--	--	19.82	--
Non-Current Liabilities	0.00	162.64	258.70	134.75	1,540.92
Current Liabilities	1.93	803.47	324.36	138.85	130.79
Total Liabilities	200.62	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	0.00	1,018.53	1,452.73	286.64	1,102.50
Current Assets	157.31	333.96	1,618.76	405.30	739.01
Total Assets	200.62	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	0.00	188.87	190.17	81.58	1,506.10
Net Current Assets	155.39	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-71.98	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	-137.02	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	-0.40	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	-209.39	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-41.86	29.58	7.38	-38.60	14.70
ROE (%)	-57.38	36.64	7.76	-43.72	110.23
ROA (%)	-47.63	16.29	6.41	-25.18	13.72
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	--	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	0.28	0.12	0.76	0.49
EBIT Growth (%)	35.52	--	--	--	--
Net Profit Growth (%)	-28.97	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	-26.56	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	-33.13	--	--	--	--

Valuation Ratios

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	-1.07	28.07	28.45	-19.80	39.02
Price / Book Value	0.56	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	1.04	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.49	0.08	0.20	8.87
Short term debt to equity ratio	0.00	0.13	0.01	0.01	0.08
Current Ratio	81.72	0.42	4.99	2.92	5.65
Quick Ratio	81.72	--	4.89	3.07	4.88
Interest Coverage	-22.81	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	Pardes Biosciences Inc (PRDS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	17.36	13.33	0.58	35.00
Asset Turnover	0.00	0.97	0.57	0.35	0.45
Receivable days	--	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly